Biomarker concordance between primary colorectal cancer and its metastases
- PMID: 30733075
- PMCID: PMC6413540
- DOI: 10.1016/j.ebiom.2019.01.050
Biomarker concordance between primary colorectal cancer and its metastases
Abstract
Background: The use of biomarkers to target anti-EGFR treatments for metastatic colorectal cancer (CRC) is well-established, requiring molecular analysis of primary or metastatic biopsies. We aim to review concordance between primary CRC and its metastatic sites.
Methods: A systematic review and meta-analysis of all published studies (1991-2018) reporting on biomarker concordance between primary CRC and its metastatic site(s) was undertaken according to PRISMA guidelines using several medical databases. Studies without matched samples or using peripheral blood for biomarker analysis were excluded.
Findings: 61 studies including 3565 patient samples were included. Median biomarker concordance for KRAS (n = 50) was 93.7% [67-100], NRAS (n = 11) was 100% [90-100], BRAF (n = 22) was 99.4% [80-100], and PIK3CA (n = 17) was 93% [42-100]. Meta-analytic pooled discordance was 8% for KRAS (95% CI = 5-10%), 8% for BRAF (95% CI = 5-10%), 7% for PIK3CA (95% CI = 2-13%), and 28% overall (95% CI = 14-44%). The liver was the most commonly biopsied metastatic site (n = 2276), followed by lung (n = 438), lymph nodes (n = 1123), and peritoneum (n = 132). Median absolute concordance in multiple biomarkers was 81% (5-95%).
Interpretation: Metastatic CRC demonstrates high concordance across multiple biomarkers, suggesting that molecular testing of either the primary or liver and lung metastasis is adequate. More research on colorectal peritoneal metastases is required.
Keywords: BRAF; Biomarker; Colorectal cancer; Concordance; PIK3CA; RAS.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Figures







Similar articles
-
High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.Oncol Rep. 2017 Feb;37(2):785-792. doi: 10.3892/or.2016.5323. Epub 2016 Dec 15. Oncol Rep. 2017. PMID: 28000889
-
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25337237 Free PMC article.
-
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6. BMC Cancer. 2017. PMID: 28068936 Free PMC article.
-
Mutations of key driver genes in colorectal cancer progression and metastasis.Cancer Metastasis Rev. 2018 Mar;37(1):173-187. doi: 10.1007/s10555-017-9726-5. Cancer Metastasis Rev. 2018. PMID: 29322354 Review.
-
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944. World J Gastroenterol. 2016. PMID: 27570430 Free PMC article. Review.
Cited by
-
RUNX1-MUC13 Interaction Activates Wnt/β-Catenin Signaling Implications for Colorectal Cancer Metastasis.Int J Biol Sci. 2024 Sep 16;20(12):4999-5026. doi: 10.7150/ijbs.98396. eCollection 2024. Int J Biol Sci. 2024. PMID: 39309442 Free PMC article.
-
Genome variation in colorectal cancer patient with liver metastasis measured by whole-exome sequencing.J Gastrointest Oncol. 2021 Apr;12(2):507-515. doi: 10.21037/jgo-21-9. J Gastrointest Oncol. 2021. PMID: 34012644 Free PMC article.
-
Progress in the Study of Colorectal Cancer Caused by Altered Gut Microbiota After Cholecystectomy.Front Endocrinol (Lausanne). 2022 Feb 24;13:815999. doi: 10.3389/fendo.2022.815999. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35282463 Free PMC article. Review.
-
Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma.Cureus. 2022 Apr 16;14(4):e24175. doi: 10.7759/cureus.24175. eCollection 2022 Apr. Cureus. 2022. PMID: 35592200 Free PMC article.
-
Adjuvant chemotherapy for isolated resectable colorectal lung metastasis: A retrospective study using inverse probability treatment weighting propensity analysis.World J Gastrointest Surg. 2024 Oct 27;16(10):3171-3184. doi: 10.4240/wjgs.v16.i10.3171. World J Gastrointest Surg. 2024. PMID: 39575266 Free PMC article.
References
-
- Noone A., Howlader N., Krapcho M., Miller D., Brest A., Yu M. 2018. SEER Cancer Statistics Review, 1975–2015. Bethesda, MD.
-
- Van Cutsem E., Group on behalf of the EGW, Cervantes A, Group on behalf of the EGW, Nordlinger B, Group on behalf of the EGW Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2014 Sep 1;25(Suppl_3):iii1–iii9. - PubMed
-
- Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous